Pfizer Inc (PFE)

32.89
NYSE : Health Care
Prev Close 32.89
Day Low/High 0.00 / 0.00
52 Wk Low/High 29.83 / 37.39
Avg Volume 20.52M
Exchange NYSE
Shares Outstanding 5.97B
Market Cap 197.54B
EPS 1.20
P/E Ratio 27.82
Div & Yield 1.28 (3.90%)

Latest News

Senate Poised to Hold Procedural Vote on Health Care

Senate Poised to Hold Procedural Vote on Health Care

Majority Leader Mitch McConnell needs 50 out of the 52 Senate Republicans to support him.

Pfizer Announces Positive Top-Line Results From The Comparative REFLECTIONS B7391003 Study For PF-06439535, A Potential Biosimilar To Avastin®1 (bevacizumab)

Pfizer Announces Positive Top-Line Results From The Comparative REFLECTIONS B7391003 Study For PF-06439535, A Potential Biosimilar To Avastin®1 (bevacizumab)

Pfizer Inc. (NYSE:PFE) today announced that the REFLECTIONS B7391003 study, a comparative, confirmatory safety and efficacy study of PF-06439535 versus Avastin® (bevacizumab), met its primary objective.

7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods

7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods

Here are the activist investor's next potential targets.

5 New Breast Cancer Treatments That Are Helping to Save Lives

5 New Breast Cancer Treatments That Are Helping to Save Lives

In the U.S., one in eight women will be diagnosed with breast cancer in their lifetime; for men, the risk is one in 1,000.

Electronic Arts, Activision Blizzard and Take-Two Interactive: 'Mad Money' Lightning Round

Electronic Arts, Activision Blizzard and Take-Two Interactive: 'Mad Money' Lightning Round

Game on: Jim Cramer is bullish on Electronic Arts, Activision Blizzard and Take-Two Interactive.

Pfizer Stock Downgraded On Expiring Viagra, Lyrica Patents

Pfizer Stock Downgraded On Expiring Viagra, Lyrica Patents

Credit Suisse lowered both its rating and price target on Pfizer's stock as expiring patents will weigh on earnings.

Don't Let Stock Picking Scare You: Cramer's 'Mad Money' Recap (Wednesday 7/19/17)

Don't Let Stock Picking Scare You: Cramer's 'Mad Money' Recap (Wednesday 7/19/17)

Jim Cramer says do your homework, be informed and don't let the wise guys trip you up with their warnings about 'single-stock risk.'

Novartis Tops Q2 Earnings Estimate, Boosts Alcon Full Year Sales Guidance

Novartis Tops Q2 Earnings Estimate, Boosts Alcon Full Year Sales Guidance

Novartis sees stronger full-year Alcon sales

10 Sectors That Will Profit Big-Time From Oil's Crash

10 Sectors That Will Profit Big-Time From Oil's Crash

Oil prices are tumbling down. Bad news for companies and petro states, but great news at the pump and for these ten industries...

These Are the Best Growth Stocks Right Now in Biotech

These Are the Best Growth Stocks Right Now in Biotech

Top names.

Potential AstraZeneca C-Suite Shuffle Rekindles Takeover Chatter

Potential AstraZeneca C-Suite Shuffle Rekindles Takeover Chatter

CEO Pascal Soriot may be on his way to Israel's Teva Pharmaceuticals ahead of key drug trial information release.

Dow Scores Record Close as Retail Roars Higher, Walmart Rallies

Dow Scores Record Close as Retail Roars Higher, Walmart Rallies

Upbeat guidance from Target inspires retail rally.

Dow on Track for Record Close as Retail Roars Higher, Walmart Rallies

Dow on Track for Record Close as Retail Roars Higher, Walmart Rallies

Upbeat guidance from Target inspires retail rally.

Healthcare Stocks Sell Off, Retail Rallies on Upbeat Guidance From Target

Healthcare Stocks Sell Off, Retail Rallies on Upbeat Guidance From Target

Upbeat guidance from Target inspires retail rally.

The New #21 Most Shorted Dow Component: Pfizer

The most recent short interest data has been released for the 06/30/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Pfizer Announces FDA Accepts Supplemental New Drug Application For XELJANZ® (tofacitinib Citrate) For The Treatment Of Adult Patients With Moderately To Severely Active Ulcerative Colitis

Pfizer Announces FDA Accepts Supplemental New Drug Application For XELJANZ® (tofacitinib Citrate) For The Treatment Of Adult Patients With Moderately To Severely Active Ulcerative Colitis

Pfizer Inc. announced today that the supplemental New Drug Application (sNDA) for XELJANZ ® (tofacitinib citrate), an investigational oral treatment for adult patients with moderately to severely active ulcerative...

FDA Advisory Committee Votes In Favor Of Pfizer's MYLOTARG (gemtuzumab Ozogamicin) For Acute Myeloid Leukemia

FDA Advisory Committee Votes In Favor Of Pfizer's MYLOTARG (gemtuzumab Ozogamicin) For Acute Myeloid Leukemia

Pfizer Inc. (NYSE:PFE) today announced that the U.

As Treasury Moves to Bring Back Inversions, Here are 7 of the Biggest Recent Deals

As Treasury Moves to Bring Back Inversions, Here are 7 of the Biggest Recent Deals

The Trump administration's creep towards scrapping certain tax regulations could revive inversion deals that have allowed U.S. companies to avoid billions of dollars in taxes.

Treasury Proposal Could Revive Inversions, Reinstate Other Tax Savings Tactics

Treasury Proposal Could Revive Inversions, Reinstate Other Tax Savings Tactics

The Treasury Department is targeting a handful of Obama-era tax rules for reform, including one that could resurrect corporate inversions.

Disney, Nvidia, Walmart and 12 Other Stocks That Could Skyrocket Going Into 2018

Disney, Nvidia, Walmart and 12 Other Stocks That Could Skyrocket Going Into 2018

From bank stocks to tech, these are my favorite names.

Alexion Investigation Believed to Have 'Minimal Impact'

Alexion Investigation Believed to Have 'Minimal Impact'

Investors shouldn't ruffle their feathers. At least, not yet.

Celgene Enters PD1 Market with BeiGene Deal

Celgene Enters PD1 Market with BeiGene Deal

Celgene acquired the rights to BeiGene's PD-1 checkpoint inhibitor, propelling the biotech giant forward in immuno-oncology research.